The FDA has approved Inrebic (fedratinib; Celgene) capsules to treat adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.
The Food and Drug Administration (FDA) has granted accelerated approval to Rozlytrek (entrectinib; Genentech)
A comparative list of biosimilars approved by the FDA including their reference products, dosage forms and indications.
The FDA has concluded that the use of entacapone to treat Parkinson disease (PD) does not increase the risk of developing prostate cancer.
The FDA is warning consumers to stop using products known as Miracle or Master Mineral Solution, Miracle Mineral Supplement, MMS, Chlorine Dioxide Protocol, and Water Purification Solution due to numerous reports of significant health issues.
This slideshow reviews drug information for Xpovio. Click here for the complete Xpovio monograph.
Potential benefits of screening do not outweigh potential harms in asymptomatic adults
The FDA has approved Turalio (pexidartinib; Daiichi Sankyo) for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery.
An Independent Data Monitoring Committee has recommended that SillaJen discontinue their phase 3 trial of Pexa-Vec (formerly JX-594) in patients with advanced hepatocellular carcinoma (HCC) following the evaluation of results from a formal pre-planned futility analysis.
The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to bempegaldesleukin (NKTR-214; Nektar Therapeutics and Bristol-Myers Squibb) in combination with nivolumab (Opdivo; Bristol-Myers Squibb) for the treatment of patients with previously untreated unresectable or metastatic melanoma.
